Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Q4 2025 value amounting to -$23.7 million.

  • Arrowhead Pharmaceuticals' Cash from Investing Activities fell 13086.98% to -$23.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$229.9 million, marking a year-over-year increase of 4364.08%. This contributed to the annual value of -$129.3 million for FY2025, which is 6922.1% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Cash from Investing Activities of -$23.7 million as of Q4 2025, which was down 13086.98% from $72.6 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $141.4 million during Q2 2025, with a 5-year trough of -$420.2 million in Q1 2025.
  • Its 5-year average for Cash from Investing Activities is -$42.3 million, with a median of -$21.6 million in 2021.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Cash from Investing Activities crashed by 83067.95% in 2024, and later skyrocketed by 193468.12% in 2025.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Cash from Investing Activities stood at -$33.4 million in 2021, then tumbled by 141.71% to -$80.7 million in 2022, then soared by 180.35% to $64.8 million in 2023, then rose by 18.62% to $76.9 million in 2024, then crashed by 130.87% to -$23.7 million in 2025.
  • Its last three reported values are -$23.7 million in Q4 2025, $72.6 million for Q3 2025, and $141.4 million during Q2 2025.